retatrutide clinical trials sign up Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and Trial of next-gen weight-loss drug

By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today

A head-to-head comparison trial with 800 patients will give direct results in late 2026

There is no medical supervision

Right now, the Zepbound savings card brings the monthly cost down to $25 for people who qualify

Retatrutide: Mechanism & Trial Results Retatrutide (LY3437943) is a triple agonist weight loss drug by Eli Lilly

We are in a new era that we have been waiting fornow the most important part is making sure that patients can access and use these medications safely, equitably and sustainably, she says.